What 9 Analyst Ratings Have To Say About Definitive Healthcare
Portfolio Pulse from Benzinga Insights
Definitive Healthcare (NASDAQ:DH) has been evaluated by 9 analysts over the past three months, with a mix of bullish and bearish opinions. The average 12-month price target has decreased by 24.6% to $5.61. Analysts have adjusted their ratings and price targets, reflecting changing market dynamics and company performance. Despite revenue growth, the company faces challenges with profitability and financial returns.
September 17, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Definitive Healthcare has received mixed analyst ratings, with a notable decrease in the average price target. Despite some revenue growth, the company faces challenges in profitability and financial returns, which may impact investor sentiment.
The decrease in the average price target by 24.6% and the mixed analyst ratings suggest a negative short-term outlook. The company's financial challenges, such as low net margin and ROE, further contribute to a bearish sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100